| Have the changes in treatment of rectal cancer made a significant difference to our patients? | |
| | |
MedLine Citation:
|
PMID: 22329182 Owner: NLM Status: In-Process |
Abstract/OtherAbstract:
|
The treatment for patients with locally advanced, resectable rectal cancer has evolved over the years. Various combinations and sequences of chemotherapy, radiation therapy, and total mesorectal excision (TME)-based surgery are the mainstay of current therapy. Preoperative combined chemoradiation, followed by surgery, is now the preferred treatment strategy, with the majority of patients receiving either infusion fluorouracil (5-FU) or capecitabine (Xeloda) with radiation. Clinical trials with oxaliplatin (Eloxatin)-based neoadjuvant chemoradiation have not shown improvement in the pathologic complete response rate (pCR) compared with 5-FU; however, final data addressing local recurrence rates and disease-free survival are pending.The use of adjuvant chemotherapy following preoperative chemoradiation and surgery has not been optimally defined. Some studies have shown that patients who obtained significant pathologic downstaging after chemoradiation and surgery have improved survival with the use of adjuvant chemotherapy. Since FOLFOX (folinic acid, 5-FU, and oxaliplatin) is the preferred adjuvant chemotherapy regimen for stage III colon cancer based on randomized clinical trial results, FOLFOX is also recommended for rectal cancer patients as an adjuvant therapy approach. |
| | |
Authors:
|
Al B Benson; José G Guillem; Bruce D Minsky |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Oncology (Williston Park, N.Y.) Volume: 25 ISSN: 0890-9091 ISO Abbreviation: Oncology (Williston Park, N.Y.) Publication Date: 2011 Dec |
Date Detail:
|
Created Date: 2012-02-14 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 8712059 Medline TA: Oncology (Williston Park) Country: United States |
Other Details:
|
Languages: eng Pagination: 1323-9 Citation Subset: IM |
Affiliation:
|
Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Feinberg School of Medicine, Chicago, Illinois, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
| Comments/Corrections | |
Comment In:
|
Oncology (Williston Park). 2011 Dec;25(14):1329-30
[PMID:
22329183
]
Oncology (Williston Park). 2011 Dec;25(14):1332, 1338 [PMID: 22329184 ] |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: [Syzran Military Hospital].
Next Document: In-transit melanoma: an individualized approach.